Navigation Links
US Oncology Research Affiliated Physicians to Present at 2011 ASCO Annual Meeting
Date:5/26/2011

rthwestGuru Sonpavde, MD, Texas OncologyYunfei Wang, Lina Asmar, PhD, US Oncology Research


  • Association of rash with improved outcomes by the addition of cetuximab (C) to second-line mitoxantrone plus prednisone (MP) for progressive mCRPC after docetaxel-based chemotherapy.Nicholas Vogelzang, MD, Comprehensive Cancer Centers of NevadaPaul Conkling, MD, Virginia Oncology AssociatesManuel Modiano, MD, Arizona Oncology Associates


  • An open-label, multicenter, randomized Phase Ib/II study of eribulin mesylate administered in combination with gemcitabine plus cisplatin versus gemcitabine plus cisplatin alone as first line therapy for locally advanced or metastatic bladder cancer.Marcus Neubauer, MD, Jody S. Garey, PharmD, Greg Nelson, Debra Patt, MD, Tom Cartwright, MD, Russ Hoverman, MD, Leslie T. Busby, MD, Barry Brooks, MD, Mark Sitarik, MD, Mike Kolodziej, MD, Roger Anderson Dr PH, Roy Beveridge, MD; on behalf of the US Oncology Pathways Task Force and Clinical Content Development Team


  • Bevacizumab therapy in advanced non-small cell lung cancer (NSCLC):  outcomes from a community oncology network.Mark Fleming, MD, Virginia Oncology AssociatesJohn Burke, MD, Rocky Mountain Cancer CentersJohn R. Caton, MD, Willamette Valley Cancer Institute and Research CenterGuru Sonpavde, MD, Texas Oncology


  • Ability of serum alkaline phosphatase (ALP) changes to complement PSA changes and predict survival in men with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel and prednisone (DP).Aimee L. Ginsburg, PharmD, Debra M. Patt MD, Jennifer Flinn, Janet L. Espirito, PharmD, Marcus A. Neubauer, MD, J. Russell Hoverman, MD, PhD, Thomas H. Cartwright, MD, Leslie T. Busby, MD, Barry Don Brooks, MD, Michael A. Kolodziej, MD, Mark A. Sitarik, MD; on behalf of the US Oncology Pathways Task Force and Clinical Content Development T
    '/>"/>


  • SOURCE US Oncology, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related medicine technology :

    1. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
    2. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
    3. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
    4. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
    5. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
    6. University of Pennsylvania School of Medicine Study Shows Significant Differences in English- and Spanish-speakers Use of Oncology Websites
    7. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
    8. Pharsight Uses FDA Disease Model to Support Oncology Drug Development
    9. US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium
    10. IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
    11. Preliminary PI-88 Phase 2 Prostate Cancer Results to be Presented at the American Society for Clinical Oncology (ASCO) 2008 Genitourinary Cancer Symposium
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)... Pa. , Jan. 23, 2015  MedScope ( www.medscope.org ... been nominated for a 2015 Connected World ... Emergency Response System (mPERS), that can be used anywhere, ... technology partner.  In nominating MedScope, ...
    (Date:1/23/2015)...  Pete Rose, baseball,s all-time hits leader, is the new spokesperson ... Ducere Pharma has announced. "Pete,s a Hall of ... him on board with Myoflex," said Ducere Pharma Chief Executive ... who is known across all generations. The passion and intensity ...
    (Date:1/23/2015)... , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), ... I trial of Lixte,s lead compound, LB‑100, is being conducted, ... John S. Kovach , M.D., the founder and President ... be completed at a single site. Accrual of patients, however, ...
    Breaking Medicine Technology:MedScope Nominated by RacoWireless for Prestigious 2015 Connected World Magazine Connected World Award 2Pete Rose bets on Myoflex to relieve aches and pains 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
    ... BOSTON and RIDGEFIELD, Conn., Oct. 30, 2010 Boehringer ... Ib study, SOUND-C1, that showed the combination of two ... BI 201335 and the polymerase inhibitor BI 207127, with ... quantifiable levels in HCV treatment-naive patients. The regimen did ...
    ... 29 AVANIR Pharmaceuticals, Inc. (Nasdaq: ... and Drug Administration (FDA) has approved NUEDEXTA™ (dextromethorphan ... treatment for pseudobulbar affect.   NUEDEXTA ... (PBA).  PBA occurs secondary to a variety of ...
    Cached Medicine Technology:Results of Boehringer Ingelheim Oral Hepatitis C Protease Inhibitor and Polymerase Inhibitor Combination Phase Ib Trial Shows Rapid Viral Response Without Use of Pegylated Interferon 2Results of Boehringer Ingelheim Oral Hepatitis C Protease Inhibitor and Polymerase Inhibitor Combination Phase Ib Trial Shows Rapid Viral Response Without Use of Pegylated Interferon 3Results of Boehringer Ingelheim Oral Hepatitis C Protease Inhibitor and Polymerase Inhibitor Combination Phase Ib Trial Shows Rapid Viral Response Without Use of Pegylated Interferon 4AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™ 2AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™ 3AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™ 4AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™ 5AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™ 6
    (Date:1/22/2015)... (PRWEB) January 22, 2015 Padre Murphy's and ... supporter of Pro Player Health Alliance (PPHA). The ... Murphy's in getting everyone, including NFL greats, treated for obstructive ... the leading groups supporting the cause in the valley. The ...
    (Date:1/22/2015)... 23, 2015 Angelweddingdress is a famous wedding ... its customers to follow it on Facebook, Twitter, and Pinterest. ... Day gift. Angelweddingdress draws a lottery every week. , Moreover, ... Feb. 28, 2015. Click Angelweddingdress homepage for more ...
    (Date:1/22/2015)... 22, 2015 The federal court overseeing thousands ... District Court, Southern District of West Virginia has upheld a ... proceeding’s first bellwether trial. In an Order dated January 21st, ... after finding that C.R. Bard had not proven a miscarriage ...
    (Date:1/22/2015)... January 22, 2015 Thousand of GranuFlo ... Care recalled its GranuFlo and NaturaLyte dialysis concentrates continue ... in U.S. District Court, District of Massachusetts, Bernstein Liebhard ... the Court has remanded a case filed by the ...
    (Date:1/22/2015)... 22, 2015 Carinsurancesavings.biz has released a new ... and dismemberment insurance . , Purchasing an accidental death ... very advantageous. This type of rider provides benefits if the ... be considered a lesser form of life insurance. , ...
    Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2
    ... KENNETT SQUARE, Pa., Aug. 19 Genesis HealthCare ... today announced that 16 of its Centers have been recognized ... presented by the American Health Care Association and National Center ... living centers from across the nation applied for the quality ...
    ... Sometimes that means trying some risky behaviors. ... cocaine, will be studied in their adolescent years. Researchers ... using drugs, having sex or engaging in delinquent behaviors, and ... The study will also closely follow the cognitive ...
    ... University of Leicester has revealed new ways to spot ... prestigious British Medical Journal , Santiago Moreno and ... the reporting of clinical trials which potentially form the ... show what mathematical adjustments can be made to remove ...
    ... chronic liver disease characterized by progressive inflammation and destruction ... usually leading to biliary cirrhosis, portal hypertension and liver ... a common cause of adult cholestatic liver diseases and ... in U.S. adults. At least 70% of PSC ...
    ... , Editorial is a Call to ... Research indicates that the social stigma that surrounds lesbian, gay, bisexual, ... as substance use, risky sexual behaviors, eating disorders, suicidal ideation, and victimization. ... Health calls on clinicians and health researchers to lead the charge ...
    ... CARDIFF, Calif., Aug.19 Rapi d ... plans to provide services to the medical cannabis industry. With ... the state of California, Rapid Fire Marketing has entered the ... to this newly-emerged industry, which includes medical doctors and cannabis ...
    Cached Medicine News:Health News:Sixteen Genesis HealthCare Centers Receive Prestigious Award for Continuous Quality Improvement in Long Term Care 2Health News:Sixteen Genesis HealthCare Centers Receive Prestigious Award for Continuous Quality Improvement in Long Term Care 3Health News:Longitudinal study investigates cocaine's impact on adolescent development 2Health News:Study finds adverse effects in treatment for primary sclerosing cholangitis 2Health News:Confronting Health Disparities Among Lesbian, Gay, Bisexual and Transgender Youth 2Health News:Confronting Health Disparities Among Lesbian, Gay, Bisexual and Transgender Youth 3Health News:Rapid Fire Marketing Enters Medical Cannabis Business 2Health News:Rapid Fire Marketing Enters Medical Cannabis Business 3
    ... Precision Hand Instruments were developed in surgeon's ... while still having an instrument with the ... the fear of the bending or breaking. ... manufactured to conform to the surgeon's hand. ...
    ... Precision Hand Instruments were developed in surgeon's ... while still having an instrument with the ... the fear of the bending or breaking. ... manufactured to conform to the surgeon's hand. ...
    ... were developed in surgeon's desire to have ... an instrument with the strength to maneuver ... the bending or breaking. Arthrotek Hand Instruments ... to the surgeon's hand. This new generation ...
    ... Stryker Universal ACL Instrumentation System has ... a variety of anterior cruciate ligament ... Universal ACL Instrumentation system and endoscopic ... obtain more reproducible anatomical graft placement ...
    Medicine Products: